THE ALUNBRIG® (brigatinib) SMART™ FREE TRIAL PROGRAM
A smart way to start patients on ALUNBRIG
The ALUNBRIG SMART Free Trial Program is a simple program offering a 1-month free trial to determine whether ALUNBRIG is appropriate for your next patient with ALK+ mNSCLC.
Ways to get your eligible patient started:
Please do not remit prescriptions to Takeda Oncology Here2Assist®.
Eligible patients must:
- Be newly diagnosed with ALK+ mNSCLC as detected by an FDA-approved test
- Be treatment-naïve to ALUNBRIG
- Not have a prior prescription for ALUNBRIG
- Have no prior enrollment history in the ALUNBRIG SMART Free Trial Program
There is no obligation to continue the use of ALUNBRIG after the free trial has been completed. A prescription will need to be written for continued use of ALUNBRIG after the free trial program.
After you write a prescription, Takeda Oncology Here2Assist can help identify financial assistance programs that may be able to help your patients with the cost of their Takeda Oncology treatment. Please see the ALUNBRIG SMART Free Trial Program brochure for more information.
Want more info on Access with ALUNBRIG?
Takeda Oncology Here2Assist® Program
Explore help for your coverage, financial, and educational needs.
1L, first-line; ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; FDA, US Food and Drug Administration; mNSCLC, metastatic NCSLC; NSCLC, non-small cell lung cancer.